Fact check
“FDA has determined that FAYUVI (rebisufligene etisparvovec-hopf), approved on September 17, 2026, manufactured by Ultragenyx Pharmaceutical Inc., meets the criteria for a priority review voucher.”
Reasoning
The claim states that the FDA determined FAYUVI (rebisufligene etisparvovec-hopf), approved on September 17, 2026, meets criteria for a priority review voucher. Without any cited FDA announcements, press releases, or reputable sources, the claim cannot be substantiated.
On confidence: No supporting evidence was provided to confirm or refute the claim.
Important context
Priority review vouchers are granted by the FDA under specific programs, and any such determination would be documented in official FDA communications or reputable news outlets.
Evidence
No retrievable evidence was found; the verdict rests on the reporting itself and is marked accordingly.
Limitations
The assessment is limited to the absence of supplied evidence; no external sources were consulted.
- Last verified:
- Oct 6, 2026, 4:10 AM CDT
- Pipeline:
- 2.1.0
- Claim type:
- Factual
Where this claim appeared
Issuance of Priority Review Voucher; Rare Pediatric Disease Product; FAYUVI (rebisufligene etisparvovec-hopf)Federal Register · Drug Administration, Human Services Department, Food, Health